Turn off the IDO: will clinical trials be successful?
- PMID: 22886661
- DOI: 10.1158/2159-8290.CD-12-0311
Turn off the IDO: will clinical trials be successful?
Abstract
Indoleamine 2,3-dioxygenase (IDO) is overexpressed in many human cancers and is believed to play a role in tumor immune evasion, but a requirement for IDO in tumor progression has not been formally shown. The study by Smith and colleagues in this issue of Cancer Discovery provides genetic evidence for the importance of IDO in tumorigenesis, which supports the use of IDO inhibitors in clinical trials in humans.
Cancer Discov; 2(8); 673-5. ©2012 AACR.
Comment on
-
IDO is a nodal pathogenic driver of lung cancer and metastasis development.Cancer Discov. 2012 Aug;2(8):722-35. doi: 10.1158/2159-8290.CD-12-0014. Epub 2012 Jul 19. Cancer Discov. 2012. PMID: 22822050 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
